recommend
manag
communityacquir
pneumonia
cap
advoc
absenc
clinic
laboratori
find
typic
bacteri
cap
antibiot
requir
howev
true
valu
clinic
laboratori
predictor
pediatr
cap
still
need
assess
prospect
cohort
studi
three
emerg
depart
enrol
children
radiolog
pneumonia
pneumonia
lung
consolid
primari
endpoint
complic
pneumonia
bacteremia
empyema
pleural
effus
secondari
endpoint
show
three
clinic
sign
unilater
hypoventil
grunt
absenc
wheez
elev
procalcitonin
pct
creactiv
protein
crp
neg
nasopharyng
viral
pcr
posit
blood
pneumococc
pcr
ppcr
significantli
associ
pneumonia
consolid
complic
pneumonia
children
neg
clinic
sign
low
crp
valu
low
probabl
pneumonia
consolid
complic
pneumonia
associ
three
clinic
sign
crp
mgl
posit
ppcr
rule
diagnosi
complic
pneumonia
posit
predict
valu
conclus
model
incorpor
clinic
sign
laboratori
marker
effect
assess
risk
pneumonia
children
neg
clinic
sign
low
crp
low
risk
pneumonia
children
posit
clinic
sign
high
crp
posit
blood
pneumococc
commun
commun
communityacquir
pneumonia
cap
remain
lead
caus
childhood
mortal
worldwid
streptococcu
pneumonia
sp
main
pathogen
bacteri
cap
pneumonia
complic
pleural
effus
empyema
bacteremia
annual
incid
cap
europ
north
america
per
children
year
old
microbiolog
etiolog
childhood
cap
vari
greatli
studi
virus
typic
atyp
bacteria
mix
viralbacteri
infect
unfortun
microbiolog
diagnosi
often
imposs
due
inaccess
infect
site
ie
lung
tissu
bronchoalveolar
lavag
complic
fact
still
gold
standard
test
diagnosi
pediatr
cap
blood
pleural
cultur
specif
posit
cap
case
blood
pneumococc
pcr
assay
target
gene
autolysin
lyta
pneumolysin
pli
seem
sensit
blood
cultur
diagnos
pneumococc
cap
use
surrog
marker
pneumococc
pneumonia
howev
recent
studi
shown
pli
pcr
may
lack
specif
posit
children
pneumococc
viridan
colon
especi
nasopharyng
pcr
therefor
util
blood
rather
nasopharyng
pcr
target
pli
lyta
gene
seem
specif
bronchoalveolar
lavag
lung
aspir
danger
routin
test
obtain
sputum
young
children
difficult
also
often
contamin
commens
oropharynx
nasopharyng
bacteri
cultur
often
posit
unreli
due
healthi
bacteri
carriag
contrast
adult
rapid
urin
sp
cpolysaccharid
assay
shown
high
rate
fals
posit
children
although
recent
studi
shown
possibl
ad
valu
antibodi
respons
four
pneumococc
surfac
protein
antibodi
one
pneumolysin
antibodi
display
encourag
result
interpret
second
week
sampl
conclus
laboratori
test
unreli
predict
caus
bacteri
involv
british
thorac
societi
recent
guidelin
manag
cap
therefor
propos
blood
test
chest
radiographi
consid
routin
investig
furthermor
recent
pid
idsa
guidelin
pediatr
cap
recommend
use
antibiot
absenc
clinic
laboratori
find
suggest
bacteri
infect
howev
exact
definit
find
allow
differenti
bacteri
viral
infect
straightforward
sinc
gold
standard
method
differenti
bacteri
viral
pneumonia
major
children
inde
treat
antibiot
often
broadspectrum
antibiot
despit
high
incid
viral
pneumonia
notabl
children
year
old
develop
clinic
laboratori
marker
could
predict
bacteri
etiolog
cap
reliabl
fashion
would
benefit
patient
physician
recent
guidelin
also
recommend
rigor
manag
followup
cap
patient
complic
bacteremia
empyema
present
studi
aim
investig
approach
combin
clinic
biolog
marker
would
accur
predict
viral
bacteri
complic
cap
ethic
approv
obtain
three
particip
hospit
relev
research
ethic
committe
geneva
canton
research
ethic
committe
human
research
ethic
committe
canton
vaud
lausann
canton
valai
medic
ethic
committe
sion
written
inform
consent
obtain
particip
parent
teenag
particip
enrol
multicent
prospect
diagnost
studi
conduct
pediatr
emerg
depart
three
swiss
tertiari
hospit
geneva
lausann
sion
consecut
includ
children
present
pneumonia
one
depart
januari
juli
inclus
criteria
month
old
year
old
fever
cough
increas
respiratori
rate
respiratori
distress
infiltr
chest
radiograph
exclus
criteria
immunodefici
chronic
lung
heart
diseas
hospitalacquir
pneumonia
blind
chest
radiograph
examin
pediatr
radiologist
infiltr
visibl
chest
radiograph
classifi
infiltr
consolid
dens
opac
without
air
bronchogram
occupi
portion
lobe
infiltr
without
consolid
densiti
linear
patchi
laci
pattern
per
bulletin
world
health
organ
cap
consolid
consid
proxi
bacteri
pneumonia
primari
endpoint
first
predict
model
complic
pneumococc
cap
defin
cap
bacteremia
pleural
effus
empyema
endpoint
second
predict
model
particip
investig
regard
follow
data
age
sex
vaccin
statu
day
care
attend
number
sibl
tobacco
exposur
clinic
examin
respiratori
rate
respiratori
distress
chest
indraw
nasal
flare
wheez
unilater
hypoventil
crackl
oxygen
satur
chest
radiograph
wbc
count
crp
pct
level
blood
cultur
blood
pneumococc
pcr
ppcr
np
viral
pcr
mycoplasmachlamydia
pcr
sevenval
pneumococc
vaccin
use
time
blood
nasopharyng
sampl
immedi
store
blood
ppcr
assay
target
pneumolysin
wbpli
autolysin
wblyta
perform
triplic
follow
dna
extract
qpcr
mixtur
contain
whole
blood
te
buffer
mm
trishcl
ph
mm
edta
glass
bead
acid
wash
sigma
vortex
min
sampl
centrifug
rpm
min
room
temperatur
dna
extract
supernat
use
dneasi
kit
qiagen
elut
water
quantit
pcr
run
realtim
pcr
system
appli
biosystem
use
absolut
qpcr
mix
abgen
reaction
mixtur
contain
dna
extract
nm
primer
probe
total
volum
cycl
condit
includ
min
min
follow
cycl
specif
primer
probe
wblyta
wbpli
acgcaatctagcagatgaagc
tggttattcgtgc
aaacgcttgatacaggg
tgca
g
g
c
g
c
c
g
g
c
tat
p
l
r
c
c
tactcgtggtttccaact
np
viral
pcr
assay
perform
per
previous
publish
protocol
assay
identifi
standard
three
type
predictor
analyz
clinic
sign
inflammatori
marker
crp
pct
specif
blood
pneumococc
nasopharyng
viral
mycoplasma
pcr
univari
multivari
logist
regress
calcul
use
softwar
statacorp
texa
usa
test
associ
cap
without
consolid
cap
without
complic
clinic
sign
crp
pcr
two
type
blood
ppcr
target
wblyta
wbpli
nasopharyng
viral
pcr
median
express
use
interquartil
rang
iqr
measur
effect
express
use
odd
ratio
or
confid
interv
ci
nonparametr
wilcoxonmannwhitney
ranksum
test
use
continu
variabl
assum
nonnorm
distribut
categor
data
pearson
chisquar
test
univari
logist
regress
use
establish
presenc
absenc
gener
associ
stepwis
multivari
logist
regress
analyz
potenti
confound
p
valu
signific
level
set
perform
type
predictor
express
use
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
posit
neg
likelihood
ratio
odd
ratio
develop
two
model
involv
three
diagnost
step
clinic
sign
inflammatori
marker
crp
specif
blood
pneumococc
pcr
likelihood
ratio
fagan
nomogram
use
calcul
posttest
probabl
step
step
posttest
probabl
calcul
diagnost
step
clinic
crp
pcr
express
preand
posttest
flow
diagram
children
pneumonia
includ
studi
month
year
old
median
year
cap
consolid
cap
without
consolid
twentysix
children
present
complic
pneumonia
includ
bacteremia
empyema
pleural
effus
cohort
sp
bacterium
respons
bacteremia
posit
blood
cultur
pleural
effus
empyema
posit
pleural
cultur
pcr
inde
staphylococcu
group
streptococcu
haemophilu
detect
total
patient
blood
ppcr
posit
wbpli
wblyta
np
mycoplasmapcr
posit
np
viral
pcr
posit
overlap
pcr
found
pneumococc
viral
posit
pneumococc
mycoplasma
posit
tabl
show
baselin
characterist
cap
without
consolid
pneumonia
without
complic
children
present
cap
consolid
complic
significantli
older
signific
differ
note
distribut
baselin
variabl
clinic
model
built
use
three
clinic
sign
significantli
associ
cap
consolid
wheez
need
bronchodil
unilater
hypoventil
grunt
least
two
associ
cap
consolid
p
blood
ppcr
show
strong
p
valu
discrimin
complic
uncompl
pneumonia
cap
without
consolid
even
control
potenti
confound
age
daycar
tobacco
vaccin
multivari
logist
regress
show
signific
associ
clinic
biolog
variabl
cap
consolid
remain
signific
comparison
crp
pct
valu
use
specif
microbiolog
pcr
result
tabl
show
signific
differ
children
posit
pneumococc
wblyta
present
high
median
crp
pct
valu
significantli
differ
wblyta
neg
one
posit
np
viral
pcr
associ
lower
median
crp
valu
neg
np
viral
case
posit
mycoplasma
np
pcr
associ
low
pct
valu
significantli
differ
neg
mycoplasma
np
pcr
studi
pct
level
predict
mycoplasma
pneumonia
better
crp
crp
level
distinguish
virus
better
pct
perform
test
differ
marker
tabl
show
clinic
model
work
well
cap
consolid
complic
pneumonia
specif
howev
sensit
enough
sensit
biomark
pneumonia
consolid
obtain
ad
crp
pct
low
cutoff
sensit
clinic
model
crp
pct
maximum
specif
found
combin
high
inflammatori
marker
crp
pct
posit
pneumococc
pcr
wblyta
ad
neg
np
viral
pcr
result
increas
specif
even
regard
biomark
complic
pneumonia
bacteremia
pleural
effus
empyema
maxim
sensit
achiev
use
crp
pct
low
cutoff
howev
optim
specif
achiev
associ
high
level
inflammatori
marker
blood
pneumococc
pcr
wblyta
specif
even
better
result
also
associ
neg
np
viral
pcr
specif
model
construct
associ
clinic
find
two
three
clinic
sign
first
step
ad
crp
second
step
blood
pneumococc
pcr
third
step
crp
use
instead
pct
due
stronger
associ
diagnosi
pneumonia
higher
figur
show
posttest
probabl
complic
pneumonia
increas
known
preval
pretest
probabl
popul
posit
clinic
model
result
crp
mgl
much
stronger
wblyta
posit
contrast
decreas
clinic
sign
absent
crp
mgl
predict
pneumonia
consolid
also
greatli
improv
use
three
step
although
lower
crp
cutoff
mgl
use
wbpli
pcr
sensit
wblyta
diagnosi
noncompl
pneumonia
studi
show
model
combin
neg
clinic
sign
low
level
inflammatori
marker
could
identifi
children
low
risk
pneumonia
consolid
two
three
clinic
signsunilater
hypoventil
grunt
absenc
wheez
show
good
specif
identifi
cap
consolid
sensit
lack
sensit
clinic
sign
emphas
previous
thu
evalu
model
combin
clinic
sign
inflammatori
marker
recent
studi
demonstr
marker
use
predict
bacteri
etiolog
cap
pct
crp
valu
better
wbc
count
differenti
bacteri
viral
cap
furthermor
present
studi
children
posit
blood
pneumococc
pcr
neg
np
viral
pcr
higher
level
inflammatori
marker
subsequ
show
ad
crp
cutoff
mgl
second
step
model
allow
us
rule
pneumonia
excel
sensit
neg
predict
valu
pneumonia
consolid
complic
pneumonia
children
neg
clinic
sign
low
crp
low
risk
pneumonia
challeng
set
pct
procalcitonin
crp
creactiv
protein
wb
whole
blood
pcr
pli
pneumolysin
lyta
autolysin
npviru
nasopharyng
viral
pcr
ppv
posit
predict
valu
npv
neg
predict
valu
clinic
sign
wheez
absent
unilater
hypoventil
present
grunt
present
consult
emerg
depart
identif
treatment
children
high
risk
develop
pneumonia
consolid
minim
unnecessari
investig
treatment
hospit
admiss
children
selflimit
viral
respiratori
ill
neg
predict
valu
rule
develop
allow
us
identifi
children
among
fever
tachypnea
low
risk
pneumonia
consolid
thu
requir
neither
chest
radiograph
immedi
antibiot
treatment
rule
applic
within
time
frame
allot
emerg
consult
clinic
evalu
crp
valu
rapidli
avail
present
studi
confirm
rule
associ
clinic
sign
inflammatori
marker
could
identifi
children
low
risk
pneumonia
order
reliabl
rule
diagnosi
pneumonia
consolid
combin
clinic
sign
crp
third
step
use
blood
pneumococc
pcr
marker
posttest
probabl
pneumonia
consolid
child
posit
clinic
sign
high
crp
posit
blood
pneumococc
pli
pcr
reach
ppv
differ
model
predict
pneumonia
studi
recent
erdman
et
al
develop
model
associ
crp
chitinas
could
rule
radiolog
pneumonia
lower
ppv
elemraid
et
al
construct
model
base
age
crp
neutrophil
count
sensit
ppv
diagnosi
radiolog
confirm
pneumonia
final
previous
develop
model
use
crp
pct
associ
posit
pneumococc
urinari
antigen
could
predict
pneumococc
pneumonia
similar
ppv
differ
model
reemphas
central
role
crp
pct
predict
pneumonia
although
identifi
children
high
risk
pneumonia
consolid
import
rapidli
identifi
children
risk
pneumonia
complic
bacteremia
pleural
effus
empyema
also
necessari
children
requir
immedi
manag
investig
often
intraven
antibiot
hospit
admiss
threestep
model
present
involv
clinic
sign
high
crp
posit
blood
ppcr
increas
posttest
probabl
complic
pneumonia
worth
note
blood
pneumococc
pcr
use
group
children
high
level
inflammatori
marker
might
explain
fact
group
children
high
level
inflammatori
marker
probabl
high
preval
pneumococc
pneumonia
therefor
influenc
falseposit
pcr
result
due
nasopharyng
colon
may
reduc
associ
neg
np
viru
pcr
increas
posit
likelihood
ratio
allow
identif
children
high
risk
complic
role
blood
np
pcr
patient
manag
probabl
evolv
futur
previous
viral
pneumococc
pcr
standard
method
etiolog
diagnosi
research
studi
howev
sinc
develop
rapid
multiplex
pcr
system
integr
sampl
prepar
amplif
detect
analysi
pcr
may
come
signific
impact
patient
manag
previous
anticip
need
minut
handsontim
result
avail
less
h
multiplex
pcr
work
within
time
frame
emerg
consult
someth
imposs
result
pneumococc
viral
pcr
examin
could
thu
use
rapidli
decisionmak
model
patient
therapi
regard
etiolog
mycoplasma
pneumonia
pcr
posit
fewer
case
children
year
old
crp
differenti
mycoplasma
pneumonia
type
pneumonia
previous
underscor
medjo
et
al
regard
pct
mycoplasma
pneumonia
associ
lower
pct
valu
nonmycoplasma
pneumonia
previous
report
moulin
et
al
one
main
limit
present
studi
common
bacteri
pneumonia
studi
lack
gold
standard
etiolog
diagnosi
radiolog
confirm
pneumonia
use
proxi
bacteri
pneumonia
numer
studi
epidemiolog
investig
clinic
trial
antimicrobi
agent
conjug
pneumococc
vaccin
efficaci
recent
nascimentocarvalho
et
al
determin
pneumonia
alveolar
consolid
sensit
pneumococc
infect
therefor
valid
diagnosi
pneumonia
radiolog
confirm
pneumonia
consolid
even
though
limit
method
reliabl
well
known
second
limit
rel
low
median
age
studi
popul
could
bia
toward
viral
etiolog
infect
lower
age
link
viral
etiolog
howev
age
group
repres
typic
pneumonia
popul
encount
pediatr
emerg
depart
furthermor
posit
result
threestep
method
use
clinic
laboratori
marker
need
extern
valid
differ
popul
propos
wide
manag
children
pneumonia
conclus
risk
pneumonia
assess
use
threestep
workup
describ
herein
step
one
identifi
children
bposit
clinic
sign
unilater
hypoventil
grunt
absenc
wheez
step
two
measur
crp
children
posit
clinic
sign
high
inflammatori
marker
step
three
could
measur
blood
pneumococc
pcr
order
effect
identifi
children
pneumonia
consolid
complic
children
neg
marker
futur
studi
propos
safetynet
clinic
followup
h
immedi
antibiot
treatment
chest
radiograph
schedul
studi
add
inform
may
use
implement
current
guidelin
manag
pneumonia
could
reduc
consumpt
antibiot
decreas
resist
save
unnecessari
investig
author
contribut
declar
author
contribut
studi
ag
agl
kk
mg
rt
ga
particip
design
ag
agl
kk
mg
rt
vm
sm
particip
activ
implement
studi
collect
data
kk
vm
ga
contribut
construct
clean
databas
ga
perform
statist
analys
wrote
initi
manuscript
author
particip
revis
manuscript
design
figur
tabl
agl
ag
activ
supervis
whole
process
fund
studi
fund
geneva
univers
hospit
divis
pediatr
emerg
medicin
professor
alain
gervaix
ethic
approv
procedur
perform
studi
involv
human
particip
accord
ethic
standard
institut
andor
nation
research
committe
declar
helsinki
later
amend
compar
ethic
standard
inform
consent
written
inform
consent
obtain
particip
parent
teenag
particip
enrol
author
declar
conflict
interest
